Skip to main content
. 2020 Sep 29;6(3):e001402. doi: 10.1136/rmdopen-2020-001402

Table 1.

Demographics of cases and controls

pSS cases invited to questionnaire pSS cases returning the questionnaire pSS cases returning the questionnaire and matched to controls Matched controls
No. of individuals 815 606 530 4425
 % Females 93 93 93 89
Age at index date (years)
 Median (IQR) 53 (42–61) 54 (41–61) 54 (43–61) 54 (42–62)
 ≤24 25 (3%) 14 (2%) 13 (2%) 117 (3%)
 25–39 137 (17%) 114 (19%) 93 (18%) 795 (18%)
 40–54 272 (33%) 197 (33%) 169 (32%) 1360 (31%)
 55–64 222 (27%) 184 (30%) 173 (33%) 1437 (32%)
 ≥65 137 (17%) 95 (16%) 82 (15%) 716 (16%)
Calendar year at index date
 1980–1985 7 (1%) 6 (1%) 0 (0%) 0 (0%)
 1985–1990 37 (5%) 23 (4%) 0 (0%) 0 (0%)
 1990–1995 59 (7%) 42 (7%) 13 (2%) 0 (0%)
 1995–2000 131 (16%) 97 (16%) 94 (18%) 506 (11%)
 2000–2005 144 (18%) 112 (18%) 110 (21%) 857 (19%)
 2005–2010 196 (24%) 161 (27%) 156 (29%) 1809 (41%)
 2010–2015 214 (26%) 159 (26%) 154 (29%) 1253 (28%)
 2015–2020 3 (0%) 3 (0%) 3 (1%) 0 (0%)
Area of residence
 Bigger cities and Southern Sweden 609 (75%) 452 (75%) 406 (77%) 3 763 (85%)
 Middle Sweden 194 (24%) 143 (24%) 115 (22%) 583 (13%)
 Northern Sweden 12 (1%) 11 (2%) 9 (2%) 79 (2%)
Highest attained education
 Primary education (≤9 years) 134 (22%) 114 (22%) 1 053 (24%)
 Secondary education (10– 12 years) 193 (32%) 172 (32%) 1 601 (36%)
 Higher education 274 (45%) 241 (45%) 1 764 (40%)
SSA and SSB status at the date of pSS diagnosis
 SSA positive 563 (69%) 418 (69%) 363 (68%)
 SSB positive 367 (45%) 269 (44%) 230 (43%)
 SSA and/or SSB positive 578 (71%) 430 (71%) 375 (71%)
No. of years between pSS diagnosis and questionnaire response date
 Median (IQR) 12 (7–19) 11 (7–18) 10 (7–16)
No. of individuals with HLA data 409 (67%) 363 (68%) 2097 (47%)

HLA, human leucocyte antigen; pSS, primary Sjögren’s syndrome; SSA, Ro/SSA autoantibodies; SSB, La/SSB autoantibodies.